{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:09:34Z","timestamp":1695575374696},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/jhh.2012.65","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T10:21:54Z","timestamp":1355998914000},"page":"445-452","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of an amlodipine\/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study)"],"prefix":"10.1038","volume":"27","author":[{"given":"S D","family":"Nesbitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Shojaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-F","family":"Maa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"issue":"17","key":"BFjhh201265_CR1","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17): 2735\u20132752.","journal-title":"Circulation"},{"issue":"7","key":"BFjhh201265_CR2","first-page":"e46","volume":"121","author":"D Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al. Heart disease and stroke statistics\u20132010 update: a report from the American Heart Association. Circulation 2010; 121 (7): e46\u2013e215.","journal-title":"Circulation"},{"key":"BFjhh201265_CR3","doi-asserted-by":"crossref","unstructured":"Yoon SS, Ostchega Y, Louis T . Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. NCHS Data Brief, 48, Hyattsville, MD: National Center for Health Statistics, 2010.","DOI":"10.1037\/e665602010-001"},{"issue":"20","key":"BFjhh201265_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2010.650","volume":"303","author":"BM Egan","year":"2010","unstructured":"Egan BM, Zhao Y, Axon RN . US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303 (20): 2043\u20132050.","journal-title":"JAMA"},{"issue":"22","key":"BFjhh201265_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1001\/archinte.167.22.2431","volume":"167","author":"ND Wong","year":"2007","unstructured":"Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS . Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003\u20132004. Arch Intern Med 2007; 167 (22): 2431\u20132436.","journal-title":"Arch Intern Med"},{"issue":"4","key":"BFjhh201265_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339 (4): 229\u2013234.","journal-title":"N Engl J Med"},{"issue":"8","key":"BFjhh201265_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1751-7176.2008.08172.x","volume":"10","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Ruilope LM . Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich) 2008; 10 (8): 624\u2013631.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl 1","key":"BFjhh201265_CR8","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc11-S011","volume":"34","author":"American Diabetes Association","year":"2011","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20132011. Diabetes Care 2011; 34 (Suppl 1): S11\u2013S61.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"BFjhh201265_CR9","first-page":"S11","volume":"35","author":"American Diabetes Association","year":"2012","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20132012. Diabetes Care 2012; 35 (Suppl 1): S11\u2013S63.","journal-title":"Diabetes Care"},{"issue":"4","key":"BFjhh201265_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Melino M, Karki S, Lee J, Heyrman R . The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30 (4): 587\u2013604.","journal-title":"Clin Ther"},{"issue":"9","key":"BFjhh201265_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2165\/00003495-200767090-00005","volume":"67","author":"BJ Epstein","year":"2007","unstructured":"Epstein BJ, Vogel K, Palmer BF . Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67 (9): 1309\u20131327.","journal-title":"Drugs"},{"issue":"7404","key":"BFjhh201265_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427.","journal-title":"BMJ"},{"issue":"1 Suppl 1","key":"BFjhh201265_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1524-6175.2007.08029.x","volume":"10","author":"GL Bakris","year":"2008","unstructured":"Bakris GL . Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008; 10 (1 Suppl 1): 27\u201332.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9489","key":"BFjhh201265_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"BFjhh201265_CR15","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417\u20132428.","journal-title":"N Engl J Med"},{"issue":"6","key":"BFjhh201265_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3109\/08037050903450468","volume":"18","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18 (6): 308\u2013347.","journal-title":"Blood Press"},{"issue":"7","key":"BFjhh201265_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1097\/HJH.0b013e3280825625","volume":"25","author":"MJ Fabia","year":"2007","unstructured":"Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J . Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25 (7): 1327\u20131336.","journal-title":"J Hypertens"},{"issue":"6","key":"BFjhh201265_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","volume":"13","author":"MR Weir","year":"2011","unstructured":"Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \u00b1 hydrochlorothiazide. J Clin Hypertens 2011; 13 (6): 404\u2013412.","journal-title":"J Clin Hypertens"},{"issue":"6","key":"BFjhh201265_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206\u20131252.","journal-title":"Hypertension"},{"issue":"2","key":"BFjhh201265_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2337\/diacare.28.2.385","volume":"28","author":"AM McNeill","year":"2005","unstructured":"McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28 (2): 385\u2013390.","journal-title":"Diabetes Care"},{"issue":"5","key":"BFjhh201265_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","volume":"56","author":"JM Flack","year":"2010","unstructured":"Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56 (5): 780\u2013800.","journal-title":"Hypertension"},{"issue":"9","key":"BFjhh201265_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25 (9): 1751\u20131762.","journal-title":"J Hypertens"},{"issue":"7","key":"BFjhh201265_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00044011-200929070-00001","volume":"29","author":"V Barrios","year":"2009","unstructured":"Barrios V, Brommer P, Haag U, Calderon A, Escobar C . Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29 (7): 427\u2013439.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"BFjhh201265_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/0044011-200929010-00002","volume":"29","author":"M Volpe","year":"2009","unstructured":"Volpe M, Brommer P, Haag U, Miele C . Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29 (1): 11\u201325.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"BFjhh201265_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2146\/ajhp060663","volume":"65","author":"K Chavanu","year":"2008","unstructured":"Chavanu K, Merkel J, Quan AM . Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008; 65 (3): 209\u2013218.","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"BFjhh201265_CR26","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1097\/00004872-200210000-00004","volume":"20","author":"G Parati","year":"2002","unstructured":"Parati G, Mancia G . Ambulatory blood pressure monitoring in clinical practice. J Hypertens 2002; 20 (10): 1925\u20131927.","journal-title":"J Hypertens"},{"issue":"4","key":"BFjhh201265_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/01.CIR.79.4.733","volume":"79","author":"JE Muller","year":"1989","unstructured":"Muller JE, Tofler GH, Stone PH . Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79 (4): 733\u2013743.","journal-title":"Circulation"},{"issue":"1","key":"BFjhh201265_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00126097-200102000-00002","volume":"6","author":"JM Neutel","year":"2001","unstructured":"Neutel JM . The importance of 24-h blood pressure control. Blood Press Monit 2001; 6 (1): 9\u201316.","journal-title":"Blood Press Monit"},{"issue":"9","key":"BFjhh201265_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1751-7176.2009.00159.x","volume":"11","author":"SG Chrysant","year":"2009","unstructured":"Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R . Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009; 11 (9): 475\u2013482.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"BFjhh201265_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1751-7176.2008.00006.x","volume":"10","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG . Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich) 2008; 10 (9): 716\u2013722.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"BFjhh201265_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00044011-200929060-00002","volume":"29","author":"M Volpe","year":"2009","unstructured":"Volpe M, Miele C, Haag U . Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009; 29 (6): 381\u2013391.","journal-title":"Clin Drug Investig"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201265","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T16:42:39Z","timestamp":1647535359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFjhh201265"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2012.65","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]},"assertion":[{"value":"2 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shawna D Nesbitt is on the speakers\u2019 bureau for Novartis, Boehringer Ingelheim and Forest Laboratories and serves on an advisory board for Daiichi Sankyo, Inc. Ali Shojaee and Jen-Fue Maa are employees of Daiichi Sankyo, Inc. Matthew R Weir is an <i>ad-hoc<\/i> scientific consultant for Daiichi Sankyo, Inc., Novartis, Amgen and NicOx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}